Em meio à pandemia que testou os limites da medicina moderna, o Brasil deu um passo silencioso mas significativo em favor daqueles que a vacinação em massa não conseguiu alcançar. A Anvisa aprovou na quinta-feira o uso emergencial do Evusheld, um tratamento com anticorpos monoclonais da AstraZeneca destinado a pacientes imunocomprometidos que não desenvolvem resposta imune adequada às vacinas disponíveis. É um reconhecimento de que a proteção coletiva, por mais abrangente que seja, sempre deixa à margem os mais vulneráveis — e de que a ciência tem a obrigação de voltar seu olhar para eles.
O Imparcial
· Feb 24, 2022
· health
· 3 min read
High
Sourcing: Verified
Anvisa approves AstraZeneca COVID-19 preventive for immunocompromised patients
The treatment addresses a critical gap for severely immunocompromised patients who cannot develop adequate immune response to vaccines and face heightened COVID-19 mortality risk.
◉
Health & Medicine
2697 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% match
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% match
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% match
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% match
Related Coverage
Folha de S.Paulo · Aug 18
Cisne mantém reinado como melhor sal entre paulistanos pela quinta vez
A marca Cisne vence pela quinta vez consecutiva a pesquisa Datafolha como melhor sal entre paulistanos, com 50% das menç…
Folha de S.Paulo · Aug 18 Projeto Quebrada Alimentada é eleito iniciativa de destaque em gastronomia pela FolhaO projeto Quebrada Alimentada, nascido no restaurante Mocotó durante a pandemia, foi eleito iniciativa de destaque pela …
UOL · Aug 17 Lucy Ramos revela que Globo consultou obstetra para cena de acidente na novelaA atriz Lucy Ramos revelou que a Globo consultou seu obstetra antes de gravar uma cena de acidente fatal enquanto ela es…
Estadão · Aug 17 Asma não impede atividade física; exercício regular ajuda no controle da doençaPesquisas confirmam que atividade física beneficia asmáticos, mas requer controle da doença e atenção a fatores ambienta…
Bias & Framing
⚖
Straightforward regulatory approval announcement with technical details and official statements; minimal bias detected in factual presentation of Anvisa decision.
Bias Direction
center
Confidence
HIGH
Official announcement framing using regulatory authority statements and scientific explanation; presents approval as routine administrative action with emphasis on safety criteria and target population specificity.
promete aumentar a resistência (promises to increase resistance) - slightly optimistic framing
novo medicamento (new medication) - emphasizes novelty
Patient advocacy groups or immunocompromised individuals' views on access and affordability
Cost/pricing information and insurance coverage details
Comparative efficacy data versus other preventive treatments
Timeline for broader availability beyond emergency use
Potential criticisms or concerns from medical professionals
Real-world effectiveness data from countries where already approved
Geopolitical Impact
🌎
Brazil's Anvisa approves AstraZeneca's Evusheld monoclonal antibody for immunocompromised COVID-19 patients, expanding pharmaceutical access but reinforcing dependence on Western biotech solutions.
Escalation Risk
low
Confidence
HIGH
Brazil
Latin America
Global pharmaceutical markets
Strengthens AstraZeneca's market position in Brazil and Latin America; reinforces Western pharmaceutical dominance in pandemic response; positions Brazil as follower of US/EU regulatory approvals rather than independent innovator; increases healthcare dependency on multinational corporations.
Similar to post-WWII pharmaceutical dependency patterns where developing nations relied on Western drug approvals, limiting domestic biotech development capacity.
Economic Lens
📈
Anvisa's approval of Evusheld expands Brazil's COVID-19 treatment options for immunocompromised patients, supporting pharmaceutical sector growth and addressing unmet medical needs in a niche but important patient segment.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical and biotechnology
Healthcare and medical services
Public health and disease prevention
Immunocompromised patients unable to receive vaccines gain access to preventive treatment, reducing hospitalization risk and healthcare costs. However, impact limited to small patient population; general population unaffected as treatment is not a vaccine substitute.
Regulatory approval signals Brazil's alignment with international health standards and may encourage further biopharmaceutical investments. Government may need to address pricing and reimbursement policies for expensive monoclonal antibody treatments and ensure equitable access through public health system.